Boehringer Ingelheim Pharmaceuticals Inc. et al v. Biocon Limited et al
| Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG |
| Biocon Limited, Biocon Pharma Limited and Biocon Pharma, Inc. |
| 1:2025cv00523 |
| April 30, 2025 |
| U.S. District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 24, 2025. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 23 PROPOSED CONSENT JUDGMENT by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) |
Filing 22
SO ORDERED, re #21 STIPULATION TO EXTEND TIME for Defendants Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) and to produce an up to date version of Biocon's ANDA No. 220117 and any related FDA correspondence to September 29, 2025, filed by Biocon Limited, Biocon Pharma, Inc., Biocon Pharma Limited. Signed by Judge Colm F. Connolly on 9/24/2025. (kmd)
|
| Filing 21 STIPULATION TO EXTEND TIME for Defendants Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) and to produce an up to date version of Biocon's ANDA No. 220117 and any related FDA correspondence to September 29, 2025 - filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Taylor, Daniel) |
|
Filing 20
SO ORDERED, re #19 STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to October 9, 2025, filed by Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH. Signed by Judge Colm F. Connolly on 9/18/2025. (kmd)
|
| Filing 19 STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to October 9, 2025 - filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) |
|
Filing 18
SO ORDERED, re #17 STIPULATION TO EXTEND TIME for Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) to September 17, 2025, filed by Biocon Limited, Biocon Pharma, Inc., Biocon Pharma Limited. Signed by Judge Colm F. Connolly on 9/12/2025. (kmd)
|
| Filing 17 STIPULATION TO EXTEND TIME for Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) to September 17, 2025 - filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Taylor, Daniel) |
| Filing 16 NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and (2) Plaintiffs' Preliminary Disclosure of Asserted Claims filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Dellinger, Megan) |
|
Filing 15
SCHEDULING ORDER: Joinder of Parties due by 9/14/2026. Amended Pleadings due by 9/14/2026. Fact Discovery completed by 9/21/2026. Expert Discovery due by 2/10/2027. Joint Claim Construction Brief due by 4/22/2026. A Markman Hearing is set for 6/18/2026 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 3/22/2027. A Final Pretrial Conference is set for 4/12/2027 at 02:00 PM in Courtroom 4B before Judge Colm F. Connolly. A 5-day Bench Trial is set to begin 4/19/2027 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 8/19/2025. (mws)
|
| Remark: The August 20, 2025 Scheduling Conference is cancelled per the filing and entry of a scheduling order with no areas of dispute. (mws) |
| Filing 14 PROPOSED ORDER -- Scheduling Order -- re #13 Order Setting Scheduling Conference, by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: #1 Letter to The Honorable Colm F. Connolly)(Dellinger, Megan) |
|
Filing 13
Order Setting Telephonic Scheduling Conference: A Telephonic Scheduling Conference is set for 8/20/2025 at 03:00 PM before Judge Colm F. Connolly. If the parties have no disputes about the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 7/30/2025. (mws)
|
| Filing 12 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Belgam, Neal) |
| Filing 11 ANSWER to #1 Complaint, filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Taylor, Daniel) |
| Filing 10 WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG: For Biocon Pharma Limited waiver sent on 5/29/2025, answer due 7/28/2025. (Dellinger, Megan) |
| Filing 9 WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG: For Biocon Pharma, Inc. waiver sent on 5/29/2025, answer due 7/28/2025. (Dellinger, Megan) |
| Filing 8 WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG: For Biocon Limited waiver sent on 5/29/2025, answer due 7/28/2025. (Dellinger, Megan) |
| Filing 7 STANDING ORDER REGARDING BRIEFING IN ALL CASES (mws) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (nmf) |
| Filing 6 Summons Issued as to Biocon Limited, Biocon Pharma Limited, and Biocon Pharma, Inc. on 4/30/2025. (Attachments: #1 Summons Issued, Biocon Pharma Limited, #2 Summons Issued, Biocon Pharma, Inc.)(jfm) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (jfm) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,853,156 B2; 9,486,526 B2; 10,034,877 B2; 11,911,388 B2. (jfm) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 03/18/2025. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 9/18/2027. (jfm) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) |
| Filing 1 COMPLAINT against Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc. (Filing fee $ 405, receipt number ADEDC-4675022) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG. (Attachments: #1 Exhibits 1-4, #2 Civil Cover Sheet)(jfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
